174 related articles for article (PubMed ID: 15779426)
21. [Achieving better control of blood sugar--understanding of oral hypoglycemic agents according to their characteristics in pharmacological action mechanism (discussion)].
Kawamori R; Kadowaki T; Ishida H
Nihon Rinsho; 2004 Apr; 62(4):831-9. PubMed ID: 15106356
[No Abstract] [Full Text] [Related]
22. Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats.
Iwase M; Nakamura U; Uchizono Y; Nohara S; Sasaki N; Sonoki K; Iida M
Eur J Pharmacol; 2005 Aug; 518(2-3):243-50. PubMed ID: 16023099
[TBL] [Abstract][Full Text] [Related]
23. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.
Voytovich MH; Haukereid C; Hjelmesaeth J; Hartmann A; Løvik A; Jenssen T
Clin Transplant; 2007; 21(2):246-51. PubMed ID: 17425753
[TBL] [Abstract][Full Text] [Related]
24. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
Dashora UK; Sibal L; Ashwell SG; Home PD
Diabet Med; 2007 Apr; 24(4):344-9. PubMed ID: 17298589
[TBL] [Abstract][Full Text] [Related]
25. [Postprandial hypoglycemia].
Mori Y
Nihon Rinsho; 2006 Sep; Suppl 3():224-9. PubMed ID: 17022536
[No Abstract] [Full Text] [Related]
26. A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients.
Shimabukuro M; Higa N; Takasu N; Tagawa T; Ueda S
Diabet Med; 2004 Sep; 21(9):983-6. PubMed ID: 15317602
[TBL] [Abstract][Full Text] [Related]
27. Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus.
Walter YH; Spratt DI; Garreffa S; McLeod JF
Eur J Clin Pharmacol; 2000 May; 56(2):129-33. PubMed ID: 10877006
[TBL] [Abstract][Full Text] [Related]
28. Navigating the choices for diabetes prevention.
Nathan DM
N Engl J Med; 2010 Apr; 362(16):1533-5. PubMed ID: 20228400
[No Abstract] [Full Text] [Related]
29. [Treatment for patients with impaired glucose tolerance].
Tawaramoto K; Kaku K
Nihon Rinsho; 2005 Feb; 63 Suppl 2():423-7. PubMed ID: 15779416
[No Abstract] [Full Text] [Related]
30. Clinical characteristics of nateglinide response as assessed by insulinogenic indices: preliminary study to determine an optimal indication for nateglinide.
Mori Y; Ishii H; Hikita M; Tajima N
Adv Ther; 2003; 20(6):352-9. PubMed ID: 15058753
[TBL] [Abstract][Full Text] [Related]
31. [Characteristic of metformin for treatment of impaired glucose tolerance].
Ishida W; Satoh J
Nihon Rinsho; 2005 Feb; 63 Suppl 2():433-7. PubMed ID: 15779418
[No Abstract] [Full Text] [Related]
32. [Effect of pioglitazone, one of TZDs, on IGT-patients].
Kobayashi M
Nihon Rinsho; 2005 Feb; 63 Suppl 2():462-70. PubMed ID: 15779423
[No Abstract] [Full Text] [Related]
33. Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
Shen L; Shah BR; Reyes EM; Thomas L; Wojdyla D; Diem P; Leiter LA; Charbonnel B; Mareev V; Horton ES; Haffner SM; Soska V; Holman R; Bethel MA; Schaper F; Sun JL; McMurray JJ; Califf RM; Krum H
BMJ; 2013 Dec; 347():f6745. PubMed ID: 24322398
[TBL] [Abstract][Full Text] [Related]
34. Diabetes prevention: can insulin secretagogues do the job?
Westerhaus B; Gosmanov AR; Umpierrez GE
Prim Care Diabetes; 2011 Jul; 5(2):73-80. PubMed ID: 21185798
[TBL] [Abstract][Full Text] [Related]
35. Nateglinide may increase high-molecular weight adiponectin in type 2 diabetic patients with hypoadiponectinemia.
Iwase M; Iino K; Doi Y; Asano T; Iida M
Diabetes Res Clin Pract; 2008 Dec; 82(3):e19-22. PubMed ID: 18849086
[TBL] [Abstract][Full Text] [Related]
36. Favorable effects of early insulin secretion by nateglinide on postprandial hyperlipidemia in patients with type 2 diabetes.
Ai M; Tanaka A; Ogita K; Shimokado K
Diabetes Care; 2006 May; 29(5):1180. PubMed ID: 16644666
[No Abstract] [Full Text] [Related]
37. Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia.
Dunning BE; Deacon R; Gutierrez C; Paladini S; Valentin MA; Foley JE
Diabetologia; 2003 Mar; 46 Suppl 1():M22-9. PubMed ID: 12652355
[TBL] [Abstract][Full Text] [Related]
38. [Dangerous postprandial glucose peaks. Risk for heart and blood vessels].
MMW Fortschr Med; 2002 May; 144(21):58. PubMed ID: 12134432
[No Abstract] [Full Text] [Related]
39. [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
Drug Ther Bull; 2003 Jul; 41(7):52-4. PubMed ID: 12879789
[TBL] [Abstract][Full Text] [Related]
40. [Type 2 diabetes. Regulating insulin according to need].
MMW Fortschr Med; 2001 Oct; 143(42):62. PubMed ID: 11697294
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]